

DO RECENT CHANGES IN TEF VALUES HAVE A MAJOR IMPACT ON TEQ OF BIOLOGICAL SAMPLES?

Arnold Schecter¹, Linda S. Birnbaum², and Shane U. Sheu¹

¹University of Texas-Houston School of Public Health, Satellite Program at University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, V8.112 Dallas, TX 75235, U.S.A

²National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency, Research Triangle Park, NC 27711 USA

Introduction

The concept of “dioxin toxic equivalency factors” (TEFs) arose from a real life public health incident, the Binghamton, New York State Office Building (BSOB) electrical system fire where a large office building was contaminated in 1981 with polychlorinated dibenzo-*p*-dioxins (PCDDs), dibenzofurans (PCDFs), and biphenyls (PCBs) from a transformer containing PCBs and tri- and tetra-chlorinated benzene. Cleanup criteria to be met were set by the New York State Health Department after reviewing the literature on these chemicals and conducting animal studies involving the mixture of the PCDDs and PCDFs found in the building and a simulated mixture prepared from chemical standards¹. PCBs were not included in the TEF studies at that time. TEFs were derived to weight the measured levels of the PCDD and PCDF congeners present in a mixture as related to the most toxic dioxin congener, 2,3,7,8-TCDD, which was defined as having a TEF of 1.0. The measured concentration of each congener was multiplied by the TEF weighting factor. The total dioxin-like toxic equivalency, TEQ, of a mixture is the sum of these products.

It has become common to present data at scientific meetings and in journals in terms of the dioxin toxic equivalents rather than the measured levels of congeners. This is done in order to estimate the toxicity of the measured congeners. Since toxic equivalency factors, which are order of magnitude consensus estimates of dioxin-like toxicity, change over time as new *in vivo*, *in vitro*, and epidemiology data as well as new interpretations are introduced, the question has arisen whether there are major differences among various TEFs and total TEQ. Presenting only measured congener levels would present a congener pattern reflecting the contamination source, but would not reflect toxicity.

We examine here recent human tissue data gathered for exposure assessment in different countries where, due to differences in congener patterns characteristic of background levels of exposure in the countries, we expected differing TEFs might lead to differently alter assessments of toxicity.

In order to depict the extent to which inferences of dioxin toxicity may have been influenced by the evolving re-evaluations of TEFs, we compare total TEQ values given for different sets of human tissue measurements by different sets of TEFs for PCDDs and PCDFs proposed by New York State, 1982¹, California 1983², the US EPA 1985³, NATO and WHO 1988^{4,5} (I-TEFs), and WHO 1998⁶. For PCBs our comparison is between Safe TEFs 1990⁷, WHO 1994 TEFs⁸, and the 1998 WHO TEFs.

Materials and Methods

Whole blood or serum was collected in chemically cleaned containers, frozen, and sent to WHO certified dioxin laboratories for analysis by high resolution gas chromatography-mass spectrometry⁹. The analytic methodology has been described previously¹⁰.

Table 1. Different TEFs

A. PCDDs and PCDFs

	New York State 1982 ¹	California 1983 ²	EPA 1985 ³	NATO (I-TEFs) 1988 ^{4,5}	WHO 1998 ⁶
PCDDs					
2378 TCDD	1	1	1	1	1
12378 PeCDD	1	1	0.2	0.5	1
HxCDD*	0.033	1	0.04	0.1	0.1
1234678 HpCDD	0	1	0.001	0.01	0.01
OCDD	0	1	0	0.001	0.0001
PCDFs					
2378 TCDF	0.333	1	0.1	0.1	0.1
12378 PeCDF	0.333	1	0.1	0.05	0.05
23478 Pe CDF	0.333	1	0.01	0.5	0.5
HxCDF**	0.011	1	0.01	0.1	0.1
HpCDF***	0	1	0.001	0.01	0.01
OCDF	0	0	0	0.001	0.0001

* HxCDD: 123478, 123678, 123789

** HxCDF: 123478, 123678, 234678, 123789

*** HpCDF: 1234678, 1234789

B. PCBs

	Safe 1990 ¹	WHO 1994 ²	WHO 1998 ³
Coplanar PCBs			
77 33'44' TCB	0.01	0.0005	0.0001
126 33'44'5 PnCB	0.1	0.1	0.1
169 33'44'55' HxPCB	0.05	0.01	0.01
Mono-ortho PCBs			
105 233'44' PnCB	0.001	0.0001	0.0001
114 2344'5 PnCB	0.001	0.0005	0.0005
118 23'44'5 PnCB	0.001	0.0001	0.0001
123 233'44' PnCB	0.001	0.0001	0.0001
156 2344'5 PnCB	0.001	0.0005	0.0005
157 23'44'5 PnCB	0.001	0.0001	0.0005
167 2344'5 PnCB	0.001	0.0005	0.00001
189 23'44'5 PnCB	0.001	0.0001	0.0001
Di-ortho PCBs			
128 22'33'44' HxPCB	0.00002	0	0
138 22'344'5' HxPCB	0.00002	0	0
153 22'44'55' HxPCB	0.00002	0	0
170 22'33'44'5 HxPCB	0.00002	0.0001	0
180 22'344'55' HxPCB	0.00002	0.00001	0

Results and Discussion

The different sets of TEFs are shown in Table 1, A for PCDDs and PCDFs, and B for PCBs.

The data are presented in Figure 1 for dioxins in toxic equivalents and for dibenzofurans in Figure 2. Data shown are from our previous publications¹¹⁻¹⁴.

California 1983 TEFs, which are no longer used, give results much higher than the other TEFs, since all congeners except OCDF are rated unity: equally toxic with TCDD. The more modest differences in TEQ totals for New York 1982, EPA 1985, 1988 I-TEFs, and WHO 1998 TEFs were consistent across countries for dioxins and for dibenzofurans. In all cases, the 1998 WHO TEFs give a higher PCDD TEQ than the three earlier systems. Relative to I-TEFs, the increase is due to the changed TEF for 1,2,3,7,8-PnCDD from 0.5 to 1. Relative to NY State and 1985 EPA TEFs, the increase is due to higher TEFs for hexa- to octa-chlorinated PCDDs.

We conclude that there is relatively little difference in total PCDD/F toxic equivalents using most major TEF schemes. This suggests that representation of relative exposure and relative toxicity in human health studies using any of the major schemes for dioxins and dibenzofurans will lead to similar conclusions.

Table 2 presents, for the American blood analyses¹², mean TEQ for dioxins, dibenzofurans and coplanar, mono-ortho and di-ortho PCBs using the older Safe and NATO schemes and the WHO 1998 TEFs. PCDD TEQ is increased 21% with the new WHO TEFs, compared with the NATO I-TEFs. The PCDF TEQ is unaffected by the single changed TEF for OCDF.

TEQ for all PCBs is about three times higher with Safe's TEFs than with the two versions of WHO TEFs. Most of the disparity in total PCB TEQ is due to TEFs for mono-ortho PCBs, given an order of magnitude higher rating by Safe than by WHO. For WHO, the dropping of TEFs for di-ortho PCBs leads to a 5% decline in total TEQ for PCBs in 1998 compared with the 1994 TEFs.

Table 2. Mean TEQ Levels of Dioxins, Dibenzofurans, and PCBs in Blood of 50 Americans, Calculated with Different Sets of TEFs pg/g (ppt) lipid basis

TEFs:	NATO for PCDD/Fs; Safe 1990 for PCBs	NATO for PCDD/Fs; WHO 1994 for PCBs	WHO 1998
PCDDs	19.5	19.5	23.5
PCDFs	7.2	7.2	7.2
PCDD/Fs	26.7	26.7	30.7
PCBs: Coplanar	13.5	10.9	10.9
Mono-ortho	50.4	5.3	5.3
Di-ortho	2.3	0.9	0
PCBs	66.2	17.1	16.2
Total TEQ	92.9	43.8	46.9

This paper does not necessarily reflect official U.S.E.P.A. policy.

Figure 1. Comparison of Dioxin TEQ levels in pooled blood samples for TEFS adopted by New York State 1982, California 1983, EPA 1985, NATO-WHO 1988, and WHO 1998 pg/g (ppt) lipid basis





Figure 2. Comparison of Dibenzofuran TEQ levels for Different TEFS pg/g (ppt) lipid



References

1. Eadon GA, Kaminsky L, Silkworth J, Aldous KM, Hilker DR, O'Keefe P, et al. Calculation of 2,3,7,8-TCDD equivalent concentrations of complex environmental contaminant mixtures. *Environ Health Perspect* 70:221-27, 1986.
2. Gravitz N, Fan A, and Neutra RR. Interim guidelines for acceptable exposure levels in office settings contaminated with PCB and PCB combustion products. California Department of Health Services, 1983.
3. US EPA Interim Procedure for Assessing Risks Associated with Exposures to Mixtures of CDD/Fs. April, 1985.
4. North Atlantic Treaty Organization, Committee on the Challenges of Modern Society. *International Toxicity Equivalency Factor (I-TEF) Method of Risk Assessment for Complex Mixtures of Dioxins and Related Compounds*, Pilot study on international information exchange on dioxins and related compounds, Report No. 176, 1988, 1-26.
5. North Atlantic Treaty Organization, Committee on the Challenges of Modern Society. *Scientific Basis for the Development of the International Toxicity Equivalency Factor (I-TEF) Method of Risk Assessment for Complex Mixtures of Dioxins and Related Compounds*, Pilot study on international information exchange on dioxins and related compounds, Report No. 178, 1988, 1-56.
6. Van den Berg M, Birnbaum L, Bosveld ATC, Brunström B, et al. Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife. *Environ Health Perspect* 106:775-92, 1998.
7. Safe S. Polychlorinated biphenyls (PCBs), dibenzo-*p*-dioxins (PCDDs), dibenzofurans (PCDFs), and related compounds: environmental and mechanistic considerations which support the development of toxic equivalency factors. *CRC Crit Rev Toxicol* 21:51-88, 1990.
8. Ahlborg UB, Becking GC, Birnbaum LS, Brouwer A, Derks HJGM, Feeley M, Golor G, Hanberg A, Larsen JC, Leim AKD, Safe SH, Schlatter C, Wærn F, Younes M, Yrjanheikki E. Toxic equivalency factors for dioxin-like PCBs. *Chemosphere* 28/6:1049-1067, 1994.
9. World Health Organization. Levels of PCBs, PCDDs and PCDFs in human milk and blood: second round of quality control studies. *Environment and Health in Europe* #37, 1-76, 1991.
10. Pöpke O, Ball M, Lis Z.A. and Scheunert K. PCDD/PCDF in whole blood samples of unexposed persons. *Chemosphere* 19:941-8, 1989.
11. Schecter A, McGee H, Stanley J.S, and Boggess K. Chlorinated dioxin, dibenzofuran, coplanar, mono-ortho, and di-ortho substituted PCB congener levels in blood and semen of Michigan Vietnam veterans compared with levels in Vietnamese exposed to Agent Orange. *Chemosphere* 27:241-52 (1993).
12. Schecter AJ, Li L, Jiang K, Fürst P, Fürst C, and Papke O. Pesticide application and increased body burden in male and female agricultural workers in China. *J Occup Environ Med* 38:906-11, 1996.
13. Schecter AJ, Pöpke O, Ball M, Grachev M, Beim A, Koptug V, Hoang Dinh Cau, Le Cao Dai, et al. Dioxin and dibenzofuran levels in human blood samples from Guam, Russia, Germany, Vietnam and the U.S.A. *Chemosphere* 25: 1129-34, 1992.
14. Schecter A, Dai LC, Thuy LTB, Quynh HT, Minh DQ, Cau HD, Phiet PH, Phuong TN, Constable JD, Baughman R, Pöpke O, Ryan JJ, Fürst P, and Räsänen S. Agent Orange and the Vietnamese: The persistence of elevated dioxin levels in human tissues. *Am. J. Public Health* 85:516-22, 1995.

